Basic Research on Gut Microbiota, New Technologies and Materials

「Possibility confirmed that combining plain yogurt containing “Bifidus Bifidobacterium BB536” with lifestyle improvements may slow the rate of aging — published in the scientific journal “Aging” — (7/27)」

「Cumulative number of published research findings: 713 (since fiscal 2022)」

「Research findings from an initiative with Kyoto University’s Katayama Laboratory and Shimadzu Corporation showed that human iPSC-derived intestinal epithelial cells increase the beneficial metabolites produced by Bifidobacterium breve MCC1274. The findings were published in the scientific journal Frontiers in Microbiology.」

「Research findings confirming that, among people suspected of having mild cognitive impairment (MCI), improvements in cognitive function from consuming Bifidobacterium breve MCC1274 correlated with blood HbA1c levels were published in the scientific journal Journal of Alzheimer’s Disease on 15 April 2021.」

「The total R&D expenses of the Group for the first-quarter cumulative consolidated period were ¥1.156 billion. There were no material changes in the status of the Group’s research and development activities during the first-quarter cumulative consolidated period.」

「◆ Confirmed that Bifidobacterium breve A1 improves cognitive function in people suspected of having mild cognitive impairment (MCI). The research paper, “Probiotic Bifidobacterium breve in improving cognitive functions of older adults with suspected mild cognitive impairment: A randomized, double-blind, placebo-controlled trial,” was published in the scientific journal Journal of Alzheimer’s Disease on 3 July 2020.」

「This study showed that oral fluid immediately after birth may be involved as one route of transmission of bifidobacteria from mothers to their children, and was published in the scientific journal Scientific Reports.」

「The total R&D expenses of the Group for the third-quarter cumulative consolidated period were ¥3.433 billion. There were no material changes in the status of the Group’s research and development activities during the third-quarter cumulative consolidated period.」

「The total R&D expenses of the Group for the second-quarter cumulative consolidated period were ¥2.350 billion. There were no material changes in the status of the Group’s research and development activities during the second-quarter cumulative consolidated period.」

「The total R&D expenses of the Group for the first-quarter cumulative consolidated period were ¥1.166 billion. There were no material changes in the status of the Group’s research and development activities during the first-quarter cumulative consolidated period.」

「These research findings were published in the online scientific journal Scientific Reports on 13 March 2019.」

「The total R&D expenses of the Group for the second-quarter cumulative consolidated period were ¥3.367 billion. There were no material changes in the status of the Group’s research and development activities during the second-quarter cumulative consolidated period.」

「The group’s total R&D expenses for the second quarter cumulative consolidated period were ¥2,202 million. There were no significant changes in the status of the group’s R&D activities during the second quarter cumulative consolidated period.」

「The group’s total R&D expenses for the first quarter cumulative consolidated period were ¥1,117 million. There were no significant changes in the status of the group’s R&D activities during the first quarter cumulative consolidated period.」

「Research on the possibility that “Bifidobacterium A1” may suppress the onset of Alzheimer’s-type dementia was published in the scientific journal Scientific Reports. Research on the possibility that “Bifidobacterium A1” may improve cognitive function in people suspected of having mild cognitive impairment was presented at the 2018 annual meeting of the Japan Society for Bioscience, Biotechnology, and Agrochemistry.」

「The group’s total R&D expenses for the third quarter cumulative consolidated period were ¥3,445 million. There were no significant changes in the status of the group’s R&D activities during the third quarter cumulative consolidated period.」

「The group’s total R&D expenses for the second quarter cumulative consolidated period were ¥2,303 million. There were no significant changes in the status of the group’s R&D activities during the second quarter cumulative consolidated period.」

「The group’s total R&D expenses for the first quarter cumulative consolidated period were ¥1,091 million. There were no significant changes in the status of the group’s R&D activities during the first quarter cumulative consolidated period.」

「The group’s total R&D expenses for the consolidated fiscal year were ¥5,362 million, broken down by segment as follows.」

「The group’s total R&D expenses for the third quarter cumulative consolidated period were ¥3,683 million. There were no significant changes in the status of the group’s R&D activities during the third quarter cumulative consolidated period.」

「The group’s total R&D expenses for the second quarter cumulative consolidated period were ¥2,457 million. There were no significant changes in the status of the group’s R&D activities during the second quarter cumulative consolidated period.」

「The group’s total R&D expenses for the first quarter cumulative consolidated period were ¥1,190 million. There were no significant changes in the status of the group’s R&D activities during the first quarter cumulative consolidated period.」

「The group will pursue basic and advanced research at the molecular and genetic levels in its search for seeds related to the development of new technologies and materials and in its research on the gut microbiota.」